Study Stopped
COVID-19 pandemic impacted recruitment
Sleep, Insulin Sensitivity, and Weight in Adolescents Post-bariatric Surgery
1 other identifier
interventional
5
1 country
1
Brief Summary
Assessing sleep and circadian health in severely obese adolescents undergoing bariatric surgery and examine relation to health outcomes including insulin sensitivity and percent weight loss to date at 1-year and evaluate the impact of sleep extension on health outcomes in this population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 20, 2019
CompletedFirst Submitted
Initial submission to the registry
December 16, 2019
CompletedFirst Posted
Study publicly available on registry
December 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 14, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 14, 2023
CompletedJuly 27, 2023
July 1, 2023
3.6 years
December 16, 2019
July 24, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Sleep duration
Total sleep time at night in hours
1 week
Study Arms (1)
Sleep Extension
EXPERIMENTALParticipants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
Interventions
Eligibility Criteria
You may qualify if:
- ages 12-21 years
- attending high school or middle school (peak period for insufficient and delayed sleep)
- completion of bariatric surgery procedure (i.e., vertical sleeve gastrectomy) within the past 2 years but not less than 6 months prior to study participation
- All must also be Tanner Stage 5
You may not qualify if:
- regular use of medications affecting sleep (e.g., stimulants, atypical antipsychotics, melatonin or other sleep aids) or insulin resistance (systemic steroids, other oral diabetes medications)
- HbA1c ≥6.5%
- intelligence quotient (IQ) \<70 or severe mental illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Jill L Kaar, PhD
University of Colorado Denver | Anschutz
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 16, 2019
First Posted
December 18, 2019
Study Start
November 20, 2019
Primary Completion
July 14, 2023
Study Completion
July 14, 2023
Last Updated
July 27, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share